Interactive evidence dashboard visualizing Health-Related Quality of Life (HRQOL) outcomes from the MONALEESA-3 trial.

Study Design & Arms

Comparison of Ribociclib + Fulvestrant vs Placebo + Fulvestrant in HR+/HER2- advanced breast cancer.

Baseline Quality of Life Scores

Mean baseline scores (±SD) for Global Health, Fatigue, and Pain (EORTC QLQ-C30). Higher Global Health is better; lower Fatigue/Pain is better.

Hazard Ratios for Deterioration (TTD)

Forest plot of Hazard Ratios (HR) for Time to Definitive Deterioration (≥10%). HR < 1 favors Ribociclib.

Median Time to Deterioration (Global Health)

Median months to definitive deterioration ≥10% in Global Health Status. Higher is better.

Change in Pain Scores at 8 Weeks

Change from baseline (EORTC QLQ-C30). Negative values indicate pain reduction (improvement).

Metric Overview Heatmap

Summary of all extracted metrics. Green indicates favorable direction for Ribociclib arm (or similarity where maintenance is goal).

Appendix: Raw Data & Provenance